Simcere has received approval from the Chinese State Food and Drug Administration to market Zanamivir, one of only two drugs cleared by the World Health Organization to treat the new H1N1 strain of influenza A.
The new drug registration approval was awarded to Simcere subsidiary Nanjing Simcere Dongyuan Pharmaceutical to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of influenza A and influenza B.
Go deeper with GlobalData
Simcere pharmaceutical group chairman and CEO Jinsheng Ren said that Zanamivir has proved very successful in the fight against the H1N1 strain of influenza A.
“With our leading domestic manufacturing facilities, well-known brand and nationwide marketing platform, Simcere is well prepared to bring this exciting drug to China,” Ren said.
GlaxoSmithKline granted a license to Simcere in 2006 to manufacture and sell Zanamivir and its formulations in China.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
